88 Lenaldomde melphalaprednsone a phase examine performed through the talaMultple Myeloma Network, nne regular monthly cycles of lenaldomde 5 ten mg day admnstered odays 1 21, melphala0.18 0.25 mg kg gveodays 1 four, and prednsone two mg kg gveodays 1 4elded aORR of 81% 53 elderly patents wth newly dagnosed MM.41 Sevepatents totalhad a CR, ncludng five of 21 patents assgned to lenaldomde 10 mg plus melphala0.18 mg kg, and two of 20 patents assgned to lenaldomde 10 mg plus melphala0.25 mg kg.One other 13 patents totalhad a VGPR.The medatme to ideal response was 4 months and PR was acheved 53% of patents following the frst cycle of treatment method.Tme to progressoLenaldomde plus dexamethasone a phase examine, lenaldomde plus dexamethasone was asso cated wth a medaTTof 32.
4 months patents who dd not undergo SCT, whereas medaTTwas not reached at the tme of publcatopatents who underwent SCT.43 The twoear TTrates have been 71% for that entre cohort, 66% the nontrans plantatogroup, and 83% the transplantatogroup.RVd a phase study, medaTTwas not reached just after a medafollow uof four months 42 patents who receved lenaldomde combnatowth bortezomb and dexamethasone.86 RMAmong LDN193189 ic50 21 elderly patents a phase examine who receved the maxmum tolerated dose of lenaldomde ten mg day for 21 days, melphala0.18 mg kg for 4 days, and prednsone two mg kg for four days of every single 28 days to get a maxmum of nne cycles, followed by lenaldomde 10 mg day for 21 of every 28 days as mantenance immediately after a medafollow uof 29.five months.The medaTTwas 28.5 months.89 General survval Lenaldomde plus dexamethasone a phase study comparng lenaldomde combna towth etherhgh dose or very low dose dexamethasone, OS was superor to the lower dose dexamethasone combnaton.
84 RVd a phase Wnt-C59 clinical trial examine, medaOS was not reached immediately after a medafollow uof 4 months.86 BRD Amid 72 evaluable patents taken care of wth BRD a phase study, actuaral EFS at twoears was 97.2%.87 The medaEFS duratowas notet reached.A single, two, and threeear survval Lenaldomde plus dexamethasone Lenaldomde plus dexamethasonehas just lately beeevaluated a randomzed managed phase examine of 445 patents wth prevously untreated MM.84,90 Survval sgnfcantly favored lenaldomde plus lower dose dexamethasone, wth a oneear survval charge of 96% compared wth 88% for lenaldomde plushgh dose dexamethasone.84 Amid patents aged 65ears, oneear survval rates for low versushgh dose dexamethasone have been 97% versus 92%, respectvely, the respectve information for patents aged 65ears were 94% versus 83%.
90 Twoear OS costs had been 87% versus 75%, respectvely.84 a land mark analyss within the 210 patents who were alve and went off review immediately after 4

months, the one and twoear OS rates amongst the 102 patents who underwent SCT were 99% and 94%, respectvely.contrast, amongst the 108 patents who dd not undergo SCT, one particular and twoear OS prices have been 85% and 70%, respectvely.